Fierce Pharma

JUNE 7, 2023

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA).

Biopharma 306

Biopharma Leads 306

Pharmaceutical Technology

SEPTEMBER 8, 2022

The speciality drug channel participants, including speciality pharmacies, biopharma companies, and distributors, are transforming their operations with automated and secure data systems and next-generation analytics, which will improve data collection, partner performance and strategy effectiveness. Discover the top speciality pharmacies.

Specialization 45

Specialization Leads Pharma Side effects 45

pharmaphorum

DECEMBER 15, 2022

The month of November saw a number of notable hires and personnel moves in biotech and pharma. Woxström, a 26-year veteran of AstraZeneca, will lead sales, marketing, and commercial operations for 30 European countries plus Canada. New CEO in at Angelini Pharma. Other biopharma hires. Two hires at Almirall.

Biopharma 52

Biopharma Pharma Sales Management 52

MedCity News

MARCH 25, 2024

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.

Biopharma 112

Biopharma Leads Pharma 112

European Pharmaceutical Review

NOVEMBER 16, 2022

For young biotechs, scaling up production brings green-field challenges, while for more established pharma a shift may be required to ensure that facilities are optimised for new ways of working. So what might that look like? Making quality more integral to production. Embracing the spirit rather than the letter of regulations.

Manufacturing 113

Manufacturing Pharma Biopharma Management 113

MedCity News

SEPTEMBER 23, 2022

Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure.

Leads 110

Leads Pharma Pharmaceutical Biopharma 110

Pharmaceutical Technology

MAY 15, 2023

Zhejiang DTRM Biopharma and Oncore Biopharma stand in second and third positions, respectively. Exelixis is a biopharmaceutical company that focuses on the development and commercialisation of small molecules for the treatment of cancer. By means of geographic reach, Cytokinetics holds the top position.

Leads 92

Leads Biopharma Pharmaceutical Pharma 92

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And of course, all of this will feed into future treatments and positive patient outcomes – the sole purpose of pharma.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

European Pharmaceutical Review

AUGUST 9, 2022

After a prolonged period of scepticism towards major moves in the mergers and acquisitions (M&A) market, leading biopharmaceutical multinationals are returning to big deal-making. In addition, and quite significantly, it was “Big Pharma” that was largely responsible for this uptick.

Pharma 69

Pharma Biopharma Leads Specialization 69

MedCity News

AUGUST 4, 2022

billion acquisition of Array Biopharma in 2019. Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4

Biopharma 110

Biopharma Leads Pharma 110

MedCity News

DECEMBER 5, 2023

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Leads 108

Leads FDA Biopharma Pharma 108

Pharmaceutical Technology

MAY 15, 2023

11 Unlock company profile Strides Pharma Science 11 Unlock company profile Sumitomo Chemical 11 Unlock company profile Eli Lilly and 9 Unlock company profile Araxes Pharma 9 Unlock company profile North & South Brother Pharmacy Investment 9 Unlock company profile Source: GlobalData Patent Analytics F.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52

Pharmaceutical Technology

MAY 15, 2023

In terms of application diversity, Ascentawits Pharmaceuticals is the top company, followed by OBI Pharma and Mabwell Shanghai Bioscience. Besides Seagen, Takeda Pharmaceutical and Immatics are the other key patent filers of peptide-based inhibitors for the treatment of cancer. By means of geographic reach, Onxeo holds the top position.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52

Pharmaceutical Technology

MARCH 14, 2023

The company’s lead asset is NBTXR3, which is based on hafnium oxide nanoparticle that is designed to destroy tumors when activated by radiotherapy. The company is involved in designing and manufacturing nanoparticles that safely enhance radiation therapy's efficacy in cancer treatment.

Leads 72

Leads Biopharma Pharmaceutical Manufacturing 72

pharmaphorum

JANUARY 9, 2023

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 on 6 th January.

Pharma 75

Pharma Biopharma Management Medicine 75

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

MedCity News

MAY 2, 2024

Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space.

Pharma 94

Pharma Leads Biopharma 94

MedCity News

JANUARY 19, 2023

Sun Pharmaceuticals is acquiring Concert Pharmaceuticals, a biotech whose lead program has positive data from two late-stage clinical trials in alopecia areata. The deal gives Sun Pharma a drug candidate that could match up against hair loss drugs from two big pharmaceutical companies.

Pharma 97

Pharma Pharmaceutical Leads Biopharma 97

Pharmaceutical Technology

MAY 24, 2023

Whilst Abliva and Ambrx Biopharma stand in second and third positions, respectively. Merck 42 Unlock company profile C. Amgen develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. Menarini Industrie Farmaceutiche Riunite. By means of geographic reach, Curis holds the top position.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Pharmacology 52

European Pharmaceutical Review

MAY 2, 2024

As a result, the market is expected to reach $719 billion by 2030, 1 Sigma Mostafa, PhD, Chief Scientific Officer at KBI Biopharma shared with EPR. What excites me most is the continuous infusion of new modalities, unique conjugates, and enabling technologies leading to more targeted and effective therapies.

Medicine 99

Medicine Manufacturing Biopharma Engineering 99

Pharmaceutical Technology

MAY 8, 2023

Hoffmann-La Roche is the leading patent filer in monoclonal antibody conjugates for cancer treatment. By means of geographic reach, Astellas Pharma holds the top position, while TRON and Eisai stand in second and third positions, respectively. Kadcyla, one of the two marketed drugs, is manufactured by Roche.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52

pharmaphorum

DECEMBER 18, 2022

Uniquely positioned, traditional patient access hubs promise to simplify the process of getting patients started on therapy and offer to provide HCPs with much-needed assistance in navigating payer requirements leading up to therapy starts. However, the cumbersome hub workflow overshadows the purported gains in productivity.

Biopharma 77

Biopharma Patients Prescription Medical 77

MedCity News

NOVEMBER 27, 2022

The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.

Leads 108

Leads Biopharma Pharma 108

pharmaphorum

DECEMBER 16, 2022

The Japanese pharma says it will now start talking to regulatory authorities around the world about potential marketing applications for zolbetuximab as a first-line treatment for patients with locally advanced unresectable or metastatic gastric and gastro-oesophageal (GEJ) cancer. Other companies developing claudin 18.2-targeted

Leads 57

Leads Biopharma Prospecting Patients 57

MedCity News

MARCH 4, 2024

Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment. The latest Akero data build on six-month results reported in 2022.

Leads 109

Leads Biopharma Pharma 109

MedCity News

FEBRUARY 12, 2024

FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.

FDA 107

FDA Leads Pharmaceutical Patients 107

MedCity News

JANUARY 24, 2023

Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.

Leads 82

Leads Biopharma Pharma 82

European Pharmaceutical Review

SEPTEMBER 12, 2023

As part of The Future of Pharma/Biopharma Analysis 2023 , which took place on 28-29 June 2023, European Pharmaceutical Review ( EPR ) gathered an expert panel to discuss developing a modern contamination control strategy. Opening the session, moderator Tim Sandle highlighted six fundamental aspects of contamination control.

Consulting 125

Consulting Biopharma Manufacturing Pharmaceutical 125

Clarivate

JANUARY 23, 2024

To learn more about how Clarivate and CMR International help pharmas future-proof their portfolios, please visit us here. She has extensive experience working with the business intelligence teams of leading pharmaceutical companies on topics such as R&D productivity , portfolio risk and protocol complexity.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

pharmaphorum

DECEMBER 4, 2022

The biopharma industry is worse, with women only accounting for 8% of CEO roles. It is critical that all managers lead their teams with flexibility and compassion, however, it’s also critical that companies prioritise appointing women to positions of leadership to show commitment to gender diversity.

Pharma 87

Pharma Management Education Leads 87

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This may best be achieved by large pharma companies, with their combined $200bn annual R&D budget, compared to smaller companies that are relying on external investment.

Biopharma 111

Biopharma Pharma Marketing Management 111

European Pharmaceutical Review

OCTOBER 4, 2023

Eli Lilly and Company has agreed to acquire the radiopharmaceutical firm POINT Biopharma Global for $1.4 POINT’s lead programmes are currently in late-stage development. The company’s other lead radiopharmaceutical candidate is PNT2003, or lutetium-177 Octreotate (177Lu-DOTATATE). The post Lilly agrees $1.4

Biopharma 99

Biopharma Medicine Leads Manufacturing 99

MedCity News

SEPTEMBER 12, 2023

The startup’s lead program, an antibody from Astellas Pharma, is a potential treatment for anti-NMDA receptor encephalitis (ANRE), a rare autoimmune inflammatory disorder. Avalon BioVentures unveiled new portfolio company Arialys Therapeutics.

Pharma 103

Pharma Leads Biopharma 103

MedCity News

FEBRUARY 7, 2024

Gilead Sciences said an independent review of interim Phase 3 data found the immunotherapy, magrolimab, led to a higher risk of death. Though Gilead is discontinuing further development of the drug in blood cancers, a review is ongoing in solid tumors.

Safety 96

Safety Leads FDA Biopharma 96

MedCity News

MAY 18, 2023

The company’s lead product candidate is in mid-stage development for wet age-related macular degeneration and non-proliferative diabetic retinopathy. By selling U.S. rights to Yutiq, EyePoint Pharmaceuticals gets $75 million cash to support its drug pipeline.

Pharma 101

Pharma Pharmaceutical Leads Biopharma 101

MedCity News

JULY 11, 2023

Septerna Therapeutics’ Series B financing will support plans to reach the clinic with a pill for a rare disease whose only approved therapy is a Takeda Pharmaceutical drug that’s leaving the market. Potential rival therapies are all injectables.

Leads 74

Leads Pharmaceutical Marketing Biopharma 74

MedCity News

JULY 18, 2023

Novartis’s acquisition of DTx Pharma brings a lead program for a rare disease with no FDA-approved therapies. But the deal could also help the pharma giant bring new RNA therapies to new places in the body, a top Novartis executive explained.

Pharma 85

Pharma FDA Leads Biopharma 85